Meeting Banner
Abstract #2995

In vivo assessment of fluoxetine human brain concentrations using fluorine MR Spectroscopy at 3T

Chu-Yu Lee1, Phil Lee1,2, Jean C. Dinh3, Andrew T Fox1, Richard M. Dubinsky4, William M. Brooks1,4, J. Steven Leeder3,5, and In-Young Choi1,4,6
1Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, United States, 2Department of Radiology, University of Kansas Medical Center, Kansas City, KS, United States, 3Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, Children’s Mercy, Kansas City, MO, United States, 4Department of Neurology, University of Kansas Medical Center, Kansas City, KS, United States, 5School of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States, 6Department of Molecular & Integrative Physiology, University of Kansas Medical Center, Kansas City, KS, United States

Fluoxetine is one of the most commonly used medications to treat mental disorders, however, 30-50% of patients fail to respond to the treatment. Thus, direct noninvasive measurements of Fluoxetine concentration in the brain may give insights into individual variations in their clinical responses. This study aimed to quantify fluoxetine concentrations in the human brain using 19F MRS at 3T. 19F MRS measurements were performed on 20 subjects with stable doses of fluoxetine over a month. The fluoxetine concentration was 30±28.2 μM and significantly correlated with their daily doses; r=0.78, p<0.0001, which promises the utility of 19F MRS for personalized medicine.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here